The spontaneous adverse drug reaction reporting system is usually the first line of defense in the detec-tion of adverse drug effects that may not be apparent during pre-marketing studies, but the cardiovascular safety signal for rofecoxib was not detected by the Adverse Event Reporting System in the US.
SPONTANEOUS REPORTS
The
spontaneous adverse drug reaction reporting system is usually the first line of
defense in the detec-tion of adverse drug effects that may not be apparent
during pre-marketing studies, but the cardiovascular safety signal for
rofecoxib was not detected by the Adverse Event Reporting System in the US.
After the VIGOR results were reported in professional meet-ings in May 2000,
the Netherlands Pharmacovigi-lance Center (Lareb) reported a cardiovascular
safety signal for rofecoxib at the annual meeting of National Centers that
participated in the WHO Programme for International Drug Monitoring in October
2000 (Edwards, 2005), but that report was not widely known in the US.
In
the US, Mukherjee and colleagues conducted a search for thrombotic or embolic
events associated with celecoxib and rofecoxib in the US Adverse Event
Reporting System in October 2000 (Mukherjee, 2001).
The
number of cases that could possibly be associ-ated with celecoxib and rofecoxib
were 99 and 102 respectively. Of the 99 patients who used rofecoxib, there were
26 cases of myocardial infarction, 43 cases of stroke, 19 cases of pulmonary
embolism or venous thrombosis, and 14 cases of miscellaneous thrombotic events.
Given the millions of doses of rofecoxib and celecoxib that had been dispensed
in the US by then, the small number of reported adverse cardiovascular events
did not represent a strong numeric signal.
Aside
from the spontaneous reporting system, there was no case report in clinical
journals on a suspected association between rofecoxib and myocardial
infarc-tion. A simple PUBMED search by one of the authors (KAC) in December
2005 using the search term ‘rofecoxib case reports’ identified 119
publi-cations, which included case reports of hepatitis, interstitial
nephritis, colitis, angioedema, anaphylac-tic shock, gynecomastia, acute renal
failure, delirium, Stevens–Johnson syndrome, congestive heart failure, and
transient visual impairment and potential drug– drug interactions in
MEDLINE-indexed journals. Not a single case of myocardial infarction was
reported in these peer-reviewed journals.
Related Topics
TH 2019 - 2025 pharmacy180.com; Developed by Therithal info.